VPAG

Market Access

Whatever people think of changes to the UK’s pricing deal, VPAG, judging the difference they make should include monitoring non-submissions to NICE.

News

The UK has cut its voluntary rebate rate for new medicines supplied to the NHS to 14.5% next year, but industry says this is "only the first step."

Market Access

Leela Barham highlights data that shows that indication-specific pricing has been used in England for at least four years and over 60 times.

Market Access

It's hard to take stock of what’s happening operationally with the UK's main pricing scheme, VPAG, given the absence of reporting by the DHSC.

Market Access

For the Financial Times (FT) Global Pharma & Biotech Summit in London 2025, pharmaphorum is providing coverage courtesy of NAVLIN Daily.

Market Access

For the Financial Times (FT) Global Pharma & Biotech Summit in London 2025, pharmaphorum is providing coverage courtesy of NAVLIN Daily.